Neutralizing Antibody Testing
Neutralizing antibodies (NAbs) can reduce the biological activity of a therapeutic product and thereby impact drug efficacy, pharmacokinetics (PK), and clinical outcomes. Detecting and understanding NAbs is essential for evaluating safety, supporting dose selection, and interpreting treatment response in clinical and nonclinical programs. NAb testing complements ADA assessments by identifying whether detected ADAs have functional consequences on drug performance.
Neutralizing Antibodies
Neutralizing antibodies (NAbs) are a functionally relevant subset of anti‑drug antibodies (ADAs) that block the biological activity of a therapeutic drug. These antibodies typically bind epitopes within or near the therapeutic’s active or functional domain, preventing interaction with the intended biological target. As a result, NAb formation may lead to reduced or abolished pharmacological activity, altered pharmacokinetics, loss of efficacy, and, in some cases, safety concerns.
Because not all ADAs are neutralizing, NAb assessment is generally performed as a follow‑up to ADA detection when there is a scientific or clinical rationale to evaluate functional impact.
Why NAb testing is important
NAbs can have a direct functional impact on drug performance. Understanding whether ADAs have neutralizing properties is essential for interpreting immunogenicity‑related changes in efficacy, PK/PD, and clinical response.
NAb testing provides insight into:
- Block binding of the therapeutic to its biological target
- Reduce or eliminate pharmacological activity
- Contribute to loss of efficacy during treatment
- Affect dosing strategies or long‑term treatment response
Because not all ADAs are neutralizing, NAb assessment is typically performed after ADA detection when there is a scientific or clinical rationale to evaluate functional impact.
Our NAb Testing Capabilities
Ligand‑Binding NAb Assays
- Tailored to therapeutic structure and mechanism of action
- Designed to model drug–target competition
- Well-suited for programs where cell‑based formats are not required
Cell‑based NAb Assays
- Functional assays designed to reflect the therapeutic’s biological mechanism
- Aligned with regulatory expectations for drugs requiring demonstration of functional inhibition
- Suitable when cell‑mediated biological activity is central to drug function
- Complements binding‑based ADA data with functional insight
Assay Development, Validation & Sample Testing
- Customized assay development for molecule‑specific requirements
- Fit‑for‑purpose or fully validated analytical methods
- Phase‑appropriate assay strategies
- Consistent and reproducible testing across preclinical and clinical studies
NAbs testing strategies
The strategy for assessing neutralizing potential in ADA‑positive samples should be based on the therapeutic’s mechanism of action (MoA), immunogenicity risk, assay performance characteristics, and the study phase. Broadly, two categories of NAb assays are applied: cell‑based assays and non‑cell‑based (ligand‑binding) assays.
Regulatory perspectives on assay formats
Regulatory agencies have historically shown a preference for cell‑based NAb assays, because these formats measure inhibition of drug activity in a biologically relevant system.
However, cell‑based assays are often labor‑intensive, highly variable, and may present challenges related to serum and drug tolerance.
Mercodia’s expertise in NAb strategies
With over 30 years of experience in immunoassay development, Mercodia supports the design and execution of fit‑for‑purpose NAb strategies, ensuring that neutralizing activity is assessed when scientifically and clinically relevant.
Non‑cell‑based assays as an alternative
Non‑cell‑based assays, such as competitive ligand‑binding formats, directly measure inhibition of drug‑target interaction.
These assays can offer:
- Higher sensitivity
- Wider dynamic range
- Increased precision
- Greater matrix tolerance
Compared with cell‑based assays, they may be an efficient alternative when functional relevance can be captured without a cellular system.
Selecting the appropriate NAb assay format
Choosing between a cell‑based and non‑cell‑based assay depends on:
- The mechanism of action (MoA)
- Assay performance characteristics
- Immunogenicity risk
- The study phase
This ensures the NAb strategy is aligned with both scientific objectives and regulatory expectations.
Have a question?
Related Resources
References
- Peek VL, Lemen DM, Konrad RJ, Wen Y. A competitive ligand binding assay for detection of neutralizing antibodies against an insulin analog [published online ahead of print, 2023 Oct 14]. J Immunol Methods. 2023;523:113575. doi:10.1016/j.jim.2023.113575
- Immunogenicity Testing of Therapeutic Protein Products —Developing and Validating Assays for Anti-Drug Antibody Detection. 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug.
- A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042). AAPS Open 7, 8 (2021). https://doi.org/10.1186/s41120-021-00039-w
